



Neuroblastoma Pathogenesis and Therapy

Guest Editor:

Dr. Saurabh Agarwal

Department of Pharmaceutical
Sciences, College of Pharmacy
and Health Sciences, St. John's
University, 8000 Utopia Parkway,
Queens, NY 11439, USA

agarwals@stjohns.edu

Deadline for manuscript
submissions:

31 July 2022

Message from the Guest Editor

Dear Colleagues,

Neuroblastoma is an aggressive pediatric cancer that originates from neural crest tissues of the sympathetic nervous system. High-risk neuroblastoma accounts for almost 15% of all pediatric cancer-related deaths, with overall survival rates lower than 50%. This situation become murkier when the majority of neuroblastoma patients relapse with an aggressive, refractory, and metastatic disease, with an overall survival rate of only 10%. Therefore, understanding the causes of neuroblastoma pathogenesis, relapse, and developing novel therapeutic approaches is mandatory to effectively cure neuroblastoma.

.....

In this Special Issue, we invite authors to contribute articles focusing on different aspects of neuroblastoma tumor biology, pathogenesis, developmental therapeutics, and treatment approaches. The collected articles in this Special Issue will further enhance our knowledge and understanding of the complex neuroblastoma pathogenesis and drive the development of novel therapeutic strategies.

Dr. Saurabh Agarwal
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPlus / SciFinder](#), and many [other databases](#).

Journal Rank: [JCR - Q1 \(Pharmacology & Pharmacy\)](#) / [CiteScore - Q2 \(Pharmaceutical Science\)](#)

Contact Us

Pharmaceuticals
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com